Drug intelligence / Profile preview

AK1960

Development stage: Preclinical
Lead developer: Asahi Kasei Pharma
Modality: Small Molecules

Overview

AK1960 is a preclinical small molecule endothelin A (ETA) receptor antagonist being developed for the treatment of refractory chronic kidney disease (CKD). Discovered by Alchemedicine using its proprietary HiSAP™ drug discovery platform, the compound was licensed to Asahi Kasei Pharma in June 2022 for worldwide development, manufacturing, and commercialization. By selectively blocking the ETA receptor, AK1960 aims to reduce renal vasoconstriction, inflammation, and fibrosis, which are primary drivers of disease progression in patients with chronic kidney disease who do not respond adequately to standard therapies.

Targets

EDNRA (Endothelin receptor type A)

Beyond the preview

Go deeper on AK1960.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AK1960.

Explore the full profile